ActiveAtlas Opportunity Score 94/100
HT942526NFRPSIA
Defense Health Agency FY26 Neurofibromatosis Synergistic Idea Award (HT942526NFRPSIA)
FY26 Neurofibromatosis Research Program Synergistic Idea Award supports collaborative NF research by two or three complementary PIs. The mandatory pre-application was due September 8, 2026 at 5:00 PM ET; full applications from applicants that completed that step are due September 22, 2026 at 11:59 PM ET.
FundingApproximately $6.4 million for about two awards. Total-cost cap: $3.2 million per award. Maximum period: three years. Cost sharing is not required.
DeadlineRequired pre-application was September 8, 2026 at 5:00 PM Eastern Time. Full application deadline for applicants that completed that step: September 22, 2026 at 11:59 PM Eastern Time.
Last verifiedSeptember 15, 2026
Required next actionDo not initiate new applicant outreach for this cycle because the mandatory September 8 pre-application deadline has passed. Route only already-preapplied multi-PI NF research teams that can verify timely first-stage submission and are completing the September 22 full application.
Broad Eligibility
Broad organization eligibility, including domestic and foreign, for-profit and nonprofit, public and private entities. Two or three PIs are required; each must be at or above assistant professor level or equivalent and commit at least 10% effort. Preliminary or published NF-relevant data are required. Cost sharing is not required.
Atlas Analysis
Atlas Opportunity Score 94/100. Large, collaborative NF research mechanism with broad organization eligibility but substantial multi-PI, preliminary-data, scientific-synergy, and two-step submission requirements. The mandatory September 8 pre-application has passed. Classification: Partner-Led / Already-Preapplied Multi-PI NF Research Team.
The Defense Health Agency Congressionally Directed Medical Research Programs has opened HT942526NFRPSIA, FY26 Neurofibromatosis Research Program Synergistic Idea Award. The mechanism supports new synergistic approaches to neurofibromatosis research involving two or three Principal Investigators who bring complementary perspectives to a central NF research problem or question.
Submission timing: The required pre-application Letter of Intent was due September 8, 2026 at 5:00 PM Eastern Time. Full application deadline: September 22, 2026 at 11:59 PM Eastern Time. Only applicants that timely completed the mandatory first-stage submission may proceed this cycle.
Funding: CDMRP expects approximately $6.4 million for about two SIA applications, with a total-cost cap of $3.2 million per award and a maximum three-year period of performance. Cost sharing is not required.
Eligibility: Eligible organizations include domestic and foreign, for-profit and nonprofit, public and private entities. Each PI must be at or above assistant professor level or equivalent and commit at least 10% effort in each budget year. One investigator serves as Initiating PI and one or two additional investigators serve as Partnering PIs; each partner submits a separate application and receives an individual award.
Research controls: Applications must include preliminary and/or published data relevant to NF and the proposed project and must demonstrate genuine scientific synergy among the participating PIs. Clinical trials are not permitted under this mechanism.
Atlas fit: Broad organization eligibility includes for-profit organizations, but the multi-PI structure, required preliminary data, NF expertise, and expired mandatory pre-application are controlling. This is not a new submission-ready Dr. Miltie direct pursuit for the current cycle. Preferred posture: Partner-Led / Already-Preapplied Multi-PI NF Research Team. Do not initiate new applicant outreach for this cycle; route only teams that can verify timely September 8 pre-application submission.
Source verificationOfficial government source · files.simpler.grants.govAtlas last verified this record September 15, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
